| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERM.12.1 |
| P953 | full work available at URL | http://www.future-drugs.com/doi/abs/10.1586/erm.12.1 |
| http://www.tandfonline.com/doi/pdf/10.1586/erm.12.1 | ||
| P698 | PubMed publication ID | 22369373 |
| P2093 | author name string | Pei Hui | |
| James Ziai | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Exclusion of BRAFV599E as a melanoma susceptibility mutation | Q73497627 | ||
| Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients | Q79363988 | ||
| MC1R germline variants confer risk for BRAF-mutant melanoma | Q79815917 | ||
| Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children | Q81258584 | ||
| BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance | Q82885422 | ||
| Moyamoya disease and moyamoya syndrome | Q95790587 | ||
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions | Q24532168 | ||
| Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation | Q24534094 | ||
| BRAF mutations in hairy-cell leukemia | Q24609980 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Targeting BRAF in thyroid cancer | Q24653496 | ||
| Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms | Q24674150 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer | Q27824825 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers | Q28206482 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Colorectal cancer due to deficiency in DNA mismatch repair function: a review | Q28262308 | ||
| Detection of BRAF V600E mutation by pyrosequencing | Q28277357 | ||
| Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization | Q28287759 | ||
| Guilty as charged: B-RAF is a human oncogene | Q28288202 | ||
| MEK kinase activity is not necessary for Raf-1 function | Q28362229 | ||
| B-raf alternative splicing is dispensable for development but required for learning and memory associated with the hippocampus in the adult mouse | Q28476616 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Rapid, efficient genotyping of clinical tumor samples by laser-capture microdissection/PCR/SSCP. | Q30663120 | ||
| Mutations of the BRAF gene in benign and malignant melanocytic lesions | Q33196532 | ||
| Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. | Q33296950 | ||
| Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling | Q33613978 | ||
| The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. | Q34084873 | ||
| Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer | Q34094717 | ||
| BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells | Q34123904 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas | Q34162272 | ||
| BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas | Q34543110 | ||
| High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. | Q34559036 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer | Q34621860 | ||
| Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules | Q34690607 | ||
| Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems | Q34998994 | ||
| Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations | Q35023498 | ||
| BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site | Q35024230 | ||
| COLD-PCR: improving the sensitivity of molecular diagnostics assays | Q35036964 | ||
| BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing | Q35446668 | ||
| Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma | Q35988122 | ||
| Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis | Q36172170 | ||
| Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma | Q36679188 | ||
| The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. | Q36681724 | ||
| BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines | Q36732681 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| Therapeutic strategies for targeting BRAF in human cancer | Q37161265 | ||
| BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer | Q37242277 | ||
| Targeting BRAF for patients with melanoma. | Q37817713 | ||
| Molecular analysis of thyroid tumors | Q37860130 | ||
| Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Q37866945 | ||
| Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. | Q38501157 | ||
| BRAF mutations in non-Hodgkin's lymphoma | Q38603361 | ||
| Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | Q39568646 | ||
| The brothers RAF. | Q39742018 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | Q40079043 | ||
| Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited | Q40185394 | ||
| Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers | Q40630939 | ||
| Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma | Q42636358 | ||
| BRAF targeted therapy changes the treatment paradigm in melanoma | Q42733647 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. | Q43251079 | ||
| Absence of exon 15 BRAF germline mutations in familial melanoma | Q44347453 | ||
| Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome | Q44394416 | ||
| BRAF and KRAS mutations in stomach cancer | Q44611189 | ||
| Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | Q45917382 | ||
| The prevalence and prognostic value of BRAF mutation in thyroid cancer | Q46200580 | ||
| BRAF T1796A transversion mutation in various thyroid neoplasms. | Q47998621 | ||
| A new technology for mutation detection | Q51647425 | ||
| Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation | Q51772302 | ||
| Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules | Q51847642 | ||
| Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer | Q51916596 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer | Q52846071 | ||
| Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors | Q53292665 | ||
| Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. | Q53352988 | ||
| BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors | Q53356308 | ||
| BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression | Q53817965 | ||
| Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study | Q54373285 | ||
| BRAFV600E detection in melanoma is highly improved by COLD-PCR. | Q54391292 | ||
| NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. | Q54570448 | ||
| Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. | Q54597071 | ||
| High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. | Q54640145 | ||
| RAF/RAS oncogenes and mismatch-repair status | Q57281056 | ||
| Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors | Q58024790 | ||
| Low Frequency of BRAF Mutations in Endometrial and in Cervical Carcinomas | Q59123138 | ||
| BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism | Q61951314 | ||
| Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma | Q73144573 | ||
| BRAF Mutation in Papillary Thyroid Carcinoma | Q73276150 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 127-138 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | BRAF mutation testing in clinical practice | |
| BRAFmutation testing in clinical practice | |||
| P478 | volume | 12 |
| Q50500974 | Adrenal malignant melanoma masquerading as a pheochromocytoma in a patient with a history of a multifocal papillary and medullary thyroid carcinoma. |
| Q21198860 | B-Raf and the inhibitors: from bench to bedside |
| Q47906055 | BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome |
| Q35802430 | BRAF gene: From human cancers to developmental syndromes |
| Q53265606 | BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation |
| Q34551705 | Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib |
| Q36392912 | Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients |
| Q28240576 | Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease |
| Q43109505 | Discrepant Results for BRAF V600E Mutation Among Different Specimens in a Case of Hairy Cell Leukemia |
| Q37601544 | High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis |
| Q54266014 | Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas |
| Q34520869 | Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma |
| Q38285393 | KRAS mutation testing in clinical practice |
| Q36809815 | Laryngeal Langerhans Cell Histiocytosis Presenting with Neck Mass in an Adult Woman |
| Q38741029 | Mismatch repair deficiency testing in clinical practice |
| Q85509862 | Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma |
| Q39501574 | Molecular pathology as the driving force for personalized oncology |
| Q38682192 | Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma |
| Q30847040 | Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine |
| Q45852947 | Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-RafV600E in cancers |
| Q43740818 | The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis |
| Q55461604 | The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. |
| Q44428665 | VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation |
Search more.